Knee Osteoarthritis Treatment: From Guidelines to Surgery

More Than 600 Million People Have This Condition

Osteoarthritis of the knee affects an estimated 654 million people worldwide, according to a 2020 Global Burden of Disease analysis — making it among the most prevalent musculoskeletal conditions on earth. In the United States, approximately 14 million people have symptomatic knee OA, and the annual cost of total knee replacements alone exceeded $35 billion by 2022. Despite this scale, the treatment landscape remains contested: several widely used interventions have been overturned by high-quality trials, while newer biological therapies are still accumulating evidence. Knowing what the evidence actually supports has direct clinical consequences.

OARSI 2019 Guidelines: The Evidence Hierarchy

The Osteoarthritis Research Society International published updated clinical practice guidelines in 2019, stratifying recommendations by patient phenotype rather than applying a one-size-fits-all protocol. Recommendations are graded as appropriate, uncertain, or not appropriate, and differ based on whether the patient has comorbidities such as cardiovascular disease, gastrointestinal disorders, or frailty.

Viscosupplementation: The Controversial Injection

Intra-articular hyaluronic acid (HA) injections — sold under brand names including Synvisc, Euflexxa, and Hyalgan — have been administered to knee OA patients since FDA approval in 1997. The proposed mechanism involves restoring the viscoelastic properties of synovial fluid, which becomes thinner and less effective as a lubricant in OA joints.

The 2012 New England Journal of Medicine trial (Henriksen et al. and associated NEJM meta-analysis by Rutjes et al.) delivered a significant blow to HA's evidence base. The Rutjes meta-analysis, analyzing 89 trials involving over 12,600 patients, found that while HA injections produced statistically significant improvements in pain, the effect size was small — a standardized mean difference of approximately 0.37 — and possibly inflated by publication bias. The clinical relevance of this effect was questioned.

• The American Academy of Orthopaedic Surgeons (AAOS) issued a "cannot recommend" statement for HA injections in 2013, downgraded from a previous conditional recommendation.
• Medicare covers HA injections; private insurers vary. The cost per series (3–5 injections) ranges from $600 to $1,800.
• Responder subgroups may exist. Some analyses suggest patients with moderate OA severity (Kellgren-Lawrence grade 2–3) and younger age derive more benefit than those with end-stage disease.
• Adverse effects are generally mild — injection-site pain, transient flare — but rare pseudoseptic reactions have been reported with cross-linked HA products.

PRP: Platelet-Rich Plasma Evidence

Platelet-rich plasma (PRP) is autologous blood that has been centrifuged to concentrate growth factors including PDGF, TGF-β, VEGF, and IGF-1. The biological premise is that local delivery of concentrated growth factors may reduce inflammation and support cartilage maintenance. A 2021 Cochrane systematic review of 13 randomized trials (1,693 participants) found moderate-certainty evidence that intra-articular PRP reduces pain at 12 months compared to placebo, with a mean difference of approximately 10 points on a 100-point VAS scale — a statistically significant but small to moderate clinical effect.

• The same Cochrane review found low-certainty evidence for functional improvement and insufficient evidence on structural modification (cartilage preservation).
• PRP formulations vary substantially across studies: leukocyte-rich vs. leukocyte-poor, single vs. multiple injections, activation method (calcium chloride, thrombin, or none) — complicating comparison across trials.
• Most insurers do not cover PRP for knee OA; out-of-pocket costs typically range from $500 to $2,000 per injection.
• A 2022 NEJM study (Bennell et al.) comparing PRP to saline placebo in 288 patients found no significant difference in pain or function at 12 months, adding a major negative trial to the literature.

Total Knee Replacement: When and Who

Total knee replacement (TKR) — more precisely termed total knee arthroplasty (TKA) — is one of the most commonly performed elective orthopedic procedures globally: approximately 790,000 are performed annually in the United States. Survivorship of modern implants at 15 years exceeds 90% in registry data from the Australian Orthopaedic Association National Joint Replacement Registry and the UK National Joint Registry.

Timing criteria are not purely radiographic. Appropriate indications for TKR require the convergence of multiple factors:

• Radiographic severity: Grade 3–4 on the Kellgren-Lawrence scale (significant joint space narrowing, osteophytes, subchondral sclerosis).
• Symptom burden: Persistent pain and functional limitation despite at least 3–6 months of conservative treatment including exercise, weight loss if applicable, analgesics, and injections.
• Patient-reported outcome threshold: NICE (UK) guidance uses Oxford Knee Score <27 (of 48) as a trigger for surgical referral evaluation.
• Age and comorbidity: No strict age cutoff exists. Younger patients (<55) risk revision surgery within their lifetime; older or medically frail patients face higher perioperative risk. Shared decision-making is essential.

Approximately 20% of TKR patients report dissatisfaction with their outcome at one year, driven primarily by persistent pain, unmet expectations, and functional limitations. Pre-operative psychosocial assessment — including catastrophizing scores and depression screening — is increasingly used to identify patients at high risk of poor outcomes.

This article is for informational and educational purposes only. Consult a qualified healthcare professional before making any medical decisions.